Crosswalk Therapeutics (Crosswalk), a seed-stage biotech company focused on developing therapies for rare diseases, has announced an asset purchase agreement with Codexis, Inc. (NASDAQ: CDXS) for the ...

Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, a well-funded DNA sequencing startup landed one of the year’s larger private funding rounds.

The company has begun searching for a successor to Dolsten, who oversaw more than 35 drug and vaccine approvals but also some notable setbacks during his time as Pfizer’s top scientist.

Antitrust regulators are set to file suit against CVS Caremark, Express Scripts and Optum Rx over how they negotiate discounts for drugs, including insulin, per the report.

Bioengineering AG announces that Dr. Roland Durner has taken over the position of Chief Executive Officer (CEO) as of July 1, ...

Calorify has formally announced its innovative, at-home test kit powered by the doubly labeled water (DLW) method, a well-validated measure of energy expenditure and body composition with applications ...

Shares of UniQure rose more than 60% Tuesday morning after the Netherlands-based biotechnology company gave an updated look at clinical trial results for its gene therapy for Huntington’s disease.

The deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel disease.

The Food and Drug Administration on Tuesday approved a new Alzheimer’s disease drug from Eli Lilly, several weeks after a panel of independent experts unanimously recommended its clearance. The drug, ...

Myricx Bio is developing a new type of payload that it thinks could work in tumors resistant to the toxins contained in ADCs like Enhertu and Trodelvy.

Having recently withdrawn its only product from the market, Amylyx hopes to rebound with a drug that regulates GLP-1 activity and is poised to enter pivotal testing early next year.

On Tuesday, regulators updated the public on their yearslong probe of PBM's business practices. The report criticizes the role of the drug middlemen, which attacked it as one-sided.